Neuro-focused Lundbeck divests US product portfolio to Recordati for $100m
This article was originally published in Scrip
Executive Summary
Italian firm Recordati has acquired a portfolio of products for the treatment of rare and other diseases from H Lundbeck for $100 million, all of which are marketed mainly in the US. The products gave Lundbeck 2011 revenues of $45 million, and are expected to bring in 2013 revenues of around $40 million.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.